BCLI Brainstorm Cell Therapeutics Inc. Return on Sales by Net Profit

Brainstorm Cell Therapeutics Inc. - graphic logo of issuer BCLI

Geopolitical instability is complicating reagent logistics and the protection of Brainstorm Cell (BCLI) patents abroad. Operating net profit margins visualize these challenges, with the latest parameter standing at 0.00. There is a serious threat of bankruptcy due to a liquidity shortage and potential regulatory rejections for ALS therapy. However, the market value already prices in R&D risks, awaiting long-term FDA approvals for the drug NurOwn.

BrainStorm Cell Therapeutics Inc. (BCLI) - Return on Sales by Net Profit from 07/04/2022 to 08/02/2025

Financial and market metric breakdowns for BrainStorm Cell Therapeutics Inc. (BCLI)

Manufactured product of Brainstorm Cell Therapeutics, Inc.

Net profitability reflects the share of profit remaining after deducting all operating and financial expenses. This metric measures the efficiency of converting revenue into bottom-line income. By analyzing the net profit margin, an investor assesses the business's resilience to rising costs. For Brainstorm Cell (BCLI), the volatility of this metric is driven by R&D expenditures. Geopolitical barriers and the logistics gap in cell therapy are currently exerting critical pressure on the company's final profitability.

Direct competitors

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|Company Sales Margin Prothena Biosciences (PRTA)|ALEC: Return on Sales by Net Profit|ANNX - Net Sales Margin|Omeros Corp. (OMER) - Net Margin|Net Margin Neurogene Inc. (NGNE)|Return on Sales by Net Profit ACIU|Net Margin VYGR|Net Margin Neumora (NMRA)|SCLX - Net Margin|Net Sales Margin TVGN (Tevogen Bio Holdings Inc.)|Net Profit Rate ACOG|Cognition Therapeutics Inc. - Net Sales Margin|IKT - Net Sales Margin|SAVA: Net Sales Margin|Assertio Holdings, Inc. - Net Profit Rate|COYA (Coya) - Net Sales Margin|Net Return on Sales VTGN (Vistagen Therapeutics)|Net Margin Ovid Rx (OVID)|Acumen Pharmaceuticals - Net Return on Sales|Net Margin CervoMed, Inc. CRVO|Net Sales Margin Alterity Therapeutics ATHE|CLNN: Return on Sales by Net Profit|PEPG (pepgen.com) - Net Return on Sales|Jupiter Neurosciences Inc (JUNS) - Net Margin|Relmada Therapeutics - Net Profit Rate|ANVS (Annovis Bio Inc) - Net Sales Margin|GRCE: Net Profit Rate|Net Margin Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Net Profit Rate|Net Margin neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Net Margin|MTVA: Return on Sales by Net Profit|NeurAxis, Inc (NRXS) - Return on Sales by Net Profit|HSDT: Net Sales Margin|PASG - Company Sales Margin|Net Margin Neuphoria Therapeutics, Inc.|Net Margin NERV|Net Sales Margin ATHA|ADXN (Addex Therapeutics Ltd) - Net Profit Rate|Net Margin alzamend.com ALZN|Company Sales Margin Cyclerion Therapeutics (CYCN)|Protagenic - Net Sales Margin|Net Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Net Sales Margin|Avenue Therapeutics Inc. (ATXI) - Net Sales Margin|CARA (Cara Therapeutics Inc.) - Net Sales Margin|Net Margin CHRO|Return on Sales by Net Profit ELYM (Eliem Therapeutics)|Net Margin ITCI (Intra-Cellular Therapies Inc.)|Net Sales Margin LBPH (Longboard Pharma)|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel